ShilpaMedicare Q1FY23 consolidated PAT drops to to Rs. 84.85 lakhs

Lincoln Pharmaceuticals Q1 FY23 consolidated profit up at Rs. 15.01 Cr

The company has reported total income of Rs. 129.96 crores during the period ended June 30, 2022.

IPCA Laboratories Q1 FY23 consolidated PAT higher at Rs. 143.06 Cr

The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.

Max Healthcare Institute Q1 FY23 consolidated PAT soars at Rs. 172.83 Cr

The company has reported total income of Rs. 1097.78 crores during the period ended June 30, 2022.

Zydus Lifesciences Q1 FY23 consolidated PAT up at Rs. 518.3 Cr

The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.

Natco Pharma consolidated Q1FY23 PAT jumps to Rs. 320.4 Cr

The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.

Unichem Laboratories Q1 FY23 consolidated loss at Rs. 23.36 Cr

The company has reported total income of Rs. 317.45 crores during the period ended June 30, 2022

Fortis Healthcare posts Q1 FY2023 consolidated PAT at Rs. 122.25 Cr

The company has reported total income of Rs. 1508.55 crores during the period ended June 30, 2022.

Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr

The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.

ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer

Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy